875
Views
37
CrossRef citations to date
0
Altmetric
Original Article

Improvement of prognosis in breast cancer in Denmark 1977–2006, based on the nationwide reporting to the DBCG Registry

, , , &
Pages 525-536 | Received 26 Nov 2007, Published online: 08 Jul 2009

References

  • Blichert-Toft, M, Christiansen, P, Mouridsen, HT. Danish Breast Cancer Cooperative Group–DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta Oncol 2008; 47:497–505.
  • Andreasen AH, Mouridsen HT, Andersen KW, Madsen M, Olesen KP. Prognose-forbedring for brystkræft. Ugeskr læger 1994; 156: 6512–6
  • Møller, S, Jensen, M-B, Eljertsen, B, Bjerre, KD, Larsen, M, Hansen, HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008; 47:506–24.
  • http://www.dbcg.dk, 14.11.07.
  • Bloom J, Richardson WW. Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359–77
  • Talman MM-L, Rasmussen, BB, Andersen, J, Christensen, IJ. Estrogen receptor analyses in the Danish Breast cancer Cooperative Group. Acta Oncol 2008; 47:789–94.
  • Kier, HV, Nielsen, BB, Bjerre, KD, Lænkholm, AV. Conventional pathological parameters recorded in the Danish Breast Cancer Cooperative Group's register 1978–2006. Acta Oncol 2008; 47:778–83.
  • Christiansen, P, Friis, E, Balslev, E, Jensen, D, Møller, S. Sentinel node biopsy in breast cancer: Five years experience from Denmark. Acta Oncol 2008; 47:561–68.
  • Thomsen, MS, Beca, M, Nielsen, HM, Pedersen, AN, Overgaard, M, Ewertz, M, et al. Post-mastectomy radiotherapy in Denmark: From 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative Group. Acta Oncol 2008; 47:654–61.
  • Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J, et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133–44
  • Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982; 38: 933–42
  • Statistics Denmark – http://www.statbank.dk, , 2009.07.
  • Axelsson, CK, Mouridsen, HT, Zedeler, K, on behalf of the Danish Breast Cancer Cooperative Group (DBCG). Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 1992;28A:1415–8.
  • Olsen AH, Njor SH, Vejborg I, Schwartz W, Dalgaard P, Jensen M-B, et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study. BMJ 2005; 330: 220–2
  • Rostgård K, Holst H, Mouridsen HT, Lynge E. Do clinical databases render population-based cancer registers obsolete. The example of breast cancer in Denmark. Cancer Chemother Control 2000; 11: 669–74
  • Hellman S. Natural history of small breast cancers. J Clin Oncol 1994; 12: 2229–34
  • Blichert-Toft, M, Nielsen, M, Düring, M, Møller, S, Rank, F, Overgaard, M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008; 47:672–81.
  • Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. for the Danish Breast Cancer Cooperative Group 82b Trial. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997; 337: 945–55
  • Overgaard M, Jensen M-B, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–8
  • Dombernowsky P, Brincker H, Hansen M, Mouridsen HT, Overgaard M, Panduro J, et al. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B. Acta Oncol 1988; 27: 691–7
  • Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, et al. Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Results from the Danish adjuvant trials. DBCG 77 C and DBCG 82 C. Acta Oncol 1988; 27: 699–705
  • et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1687–717.
  • Ejlertsen B, Mouridsen HT, Jensen M-B, Andersen J, Jensen BB, Cold S, et al. Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 2007; 43: 877–84
  • Thürlimann B, Keshaviah A, Coates AS, Mouridsen HT, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 350: 2747–57
  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Traztuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72
  • Jatoi, I, Chen, BE, Anderson, F, Rosenberg, PS. Breast cancer mortality in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007; 25 APUD.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.